Drug found that induces apoptosis in myofibroblasts reducing fibrosis in scleroderma

December 15, 2017 by Bob Yirka, Medical Xpress report

Histological section through testicular parenchyma of a boar. 1 Lumen of Tubulus seminiferus contortus, 2 spermatids, 3 spermatocytes, 4 spermatogonia, 5 Sertoli cell, 6 Myofibroblasts, 7 Leydig cells, 8 capillaries. Credit: Uwe Gille/Wikipedia
(Medical Xpress)—An international team of researchers has found that the drug navitoclax can induce apoptosis (self-destruction) in myofibroblasts in mice, reducing the spread of fibrosis in scleroderma. In their paper published in the journal Science, the group describes their study of fibrosis in scleroderma and how they used what they learned to discover the healing effects of navitoclax.

In humans (and mice), is seen as a type of scarring that causes damage to organs, sometimes leading to death. Prior research has shown that fibrosis is caused by myofibroblasts, which are that are normally involved in helping the body heal. But sometimes, they continue working even after the healing is over, causing scarring. The myofibroblasts continue working, the researchers explain, because they fail to self-destruct as they are supposed to. In this new effort, the researchers sought to learn more about this process by studying one form of fibrosis called scleroderma, which, as its name suggests, starts in the skin before moving to organs.

In taking a closer look at the myofibroblast cell, the researchers found that its mitochondria contained the type of protein normally involved in apoptosis, but the cell did not die—likely, they thought, because it was not being activated. That discovery led them to look at a family of proteins called BCL-2, which either induce or prevent the onset of apoptosis. Further study led to one particular protein called Bcl-xL, which stops apoptosis—they found it in abundance in myofibroblasts. That led them to wonder if there might be a that could reduce those levels, thereby allowing the cells to die a proper death. They noted that a drug called ABT-263, more easily remembered as the drug navitoclax, currently undergoing clinical trials as a cancer treatment, also did just what they were looking for.

Testing the drug in mice showed not only that they were on the right track, but that the drug could actually cause the to die on schedule as they were supposed to, preventing new fibrosis from occurring. But they also noticed something else—the drug appeared to reduce existing fibrosis, as well, though the team could not explain why.

Much more work will have to be done with the drug before it can be considered as a treatment for fibrosis in humans, but at this time, the researchers note, it looks promising.

Explore further: Radiation and pulmonary fibrosis

More information: David Lagares et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aal3765

Abstract
Persistent myofibroblast activation distinguishes pathological fibrosis from physiological wound healing, suggesting that therapies selectively inducing myofibroblast apoptosis could prevent progression and potentially reverse established fibrosis in diseases such as scleroderma, a heterogeneous autoimmune disease characterized by multiorgan fibrosis. We demonstrate that fibroblast-to-myofibroblast differentiation driven by matrix stiffness increases the mitochondrial priming (proximity to the apoptotic threshold) of these activated cells. Mitochondria in activated myofibroblasts, but not quiescent fibroblasts, are primed by death signals such as the proapoptotic BH3-only protein BIM, which creates a requirement for tonic expression of the antiapoptotic protein BCL-XL to sequester BIM and ensure myofibroblast survival. Myofibroblasts become particularly susceptible to apoptosis induced by "BH3 mimetic" drugs inhibiting BCL-XL such as ABT-263. ABT-263 displaces BCL-XL binding to BIM, allowing BIM to activate apoptosis on stiffness-primed myofibroblasts. Therapeutic blockade of BCL-XL with ABT-263 (navitoclax) effectively treats established fibrosis in a mouse model of scleroderma dermal fibrosis by inducing myofibroblast apoptosis. Using a BH3 profiling assay to assess mitochondrial priming in dermal fibroblasts derived from patients with scleroderma, we demonstrate that the extent of apoptosis induced by BH3 mimetic drugs correlates with the extent of their mitochondrial priming, indicating that BH3 profiling could predict apoptotic responses of fibroblasts to BH3 mimetic drugs in patients with scleroderma. Together, our findings elucidate the potential efficacy of targeting myofibroblast antiapoptotic proteins with BH3 mimetic drugs in scleroderma and other fibrotic diseases.

Related Stories

Radiation and pulmonary fibrosis

November 16, 2017
Radiation-induced pulmonary fibrosis—tissue scarring that can permanently impair lung function—limits the delivery of therapeutic radiation doses to non-small cell lung cancer.

Pulmonary fibrosis: Between a ROCK and a hard place

February 22, 2013
Pulmonary fibrosis is a scarring or thickening of the lungs that causes shortness of breath, a dry cough, fatigue, chest discomfort, weight loss, a decrease in the ability of the lungs to transmit oxygen to the blood stream, ...

New tools to combat kidney fibrosis

October 16, 2017
Interstitial fibrosis – excessive tissue scarring – contributes to chronic kidney disease, which is increasing in prevalence in the United States.

Molecular pathway offers treatment targets for pulmonary fibrosis, related conditions

November 15, 2017
A study led by investigators at Massachusetts General Hospital (MGH) and University Health Network (UHN) in Toronto has identified a molecular pathway that appears to be critical to the development of fibrosis - scarring ...

Thyroid hormone therapy heals lung fibrosis in animal study

December 4, 2017
Thyroid hormone therapy significantly resolves fibrosis, or scarring, in the lungs of mice, increasing their survival from disease, a Yale-led study shows. These provide a novel insight into the development of pulmonary fibrosis ...

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.